Variations in sex hormone metabolism genes, postmenopausal hormone therapy and risk of endometrial cancer

✍ Scribed by Pedram Razavi; Eunjung Lee; Leslie Bernstein; David Van Den Berg; Pamela L. Horn-Ross; Giske Ursin

• Book ID: 102864362
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: French
• Weight: 806 KB
• Volume: 130
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.26163

✦ Synopsis

Abstract

We investigated whether variants in sex steroid hormone metabolism genes modify the effect of hormone therapy (HT) on endometrial cancer risk in postmenopausal non‐Hispanic white women. A nested case–control study was conducted within the California Teachers Study (CTS). We genotyped htSNPs in six genes involved in the hormone metabolism in 286 endometrial cancer cases and 488 controls. Odds ratio (OR) and 95% confidence interval (CI) were estimated for each haplotype using unconditional logistic regression, adjusting for age. The strongest interaction was observed between duration of estrogen therapy (ET) use and haplotype 1A in CYP11A1 (p~interaction~ = 0.0027; p~interaction~ = 0.010 after correcting for multiple testing within each gene). The OR for endometrial cancer per copy of haplotype 1A was 2.00 (95% CI: 1.05–3.96) for long‐term ET users and 0.90 (95% CI: 0.69–1.18) for never users. The most significant interaction with estrogen‐progestin therapy (EPT) was found for two haplotypes on CYP19A1 and EPT use (haplotype 4A, p~interaction~ = 0.024 and haplotype 3B, p~interaction~ = 0.043). However, neither this interaction, nor the ET or EPT interactions for any other genes, was statistically significant after correction for multiple testing. Variations in CYP11A1 may modify the effect of ET use on risk of postmenopausal endometrial cancer; however, larger studies are needed to explore these findings further.